Erlotinib in non-small-cell lung cancer

Cesare Gridelli ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Antonio Rossi ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Paolo Maione ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Giuseppe Colantuoni ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Filomena Del Gaizo ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Carmine Ferrara ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD,

Dario Nicolella ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD &

Ciro Guerriero ‘S.G. Moscati’ Hospital, Division of Medical Oncology, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, Italy +39 0825 203573; +39 0825 203556; [email protected]

, MD show all

Abstract

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is a common feature in solid malignancies, including non-small-cell lung cancer (NSCLC), and is associated with poor clinical prognosis. Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a significant improvement in median survival, quality of life and related symptoms in an unselected population of advanced NSCLC patients in the second- or third-line setting. Erlotinib is well tolerated (with common toxicities including rash and diarrhoea) when administered at a standard oral daily dose of 150 mg. Further investigations are ongoing to contribute to our understanding of the role of erlotinib in NSCLC treatment.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Erlotinib in non-small-cell lung cancer

Related Research Data

Information for

Open access

Opportunities

Help and information

Erlotinib in non-small-cell lung cancer

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature